Predictors of Survival and Time to Progression to Myeloid Neoplasm in Patients with Clonal Cytopenias
Ahmad Nanaa(Mayo Clinic), Aref Al‐Kali(Mayo Clinic), Dragan Jevremović(Mayo Clinic in Arizona), Rama Nana(Mayo Clinic in Arizona), Min Shi(Mayo Clinic in Arizona), Mohamed E. Salama(The University of Texas at San Antonio Health Science Center), Cynthia Hengel(Mayo Clinic in Arizona), Zhuoer Xie(Mayo Clinic), Hassan B. Alkhateeb(Mayo Clinic), Mrinal M. Patnaik(Mayo Clinic), Patricia T. Greipp(Mayo Clinic), Rong He(Mayo Clinic), William J. Hogan(Mayo Clinic), Mark R. Litzow(Mayo Clinic in Arizona), Phuong L. Nguyen(St. Jude Children's Research Hospital), Michael Timm(Mayo Clinic), Susan M. Geyer(Mayo Clinic in Florida), David S. Viswanatha(Mayo Clinic), Mithun Vinod Shah(Mayo Clinic in Arizona)
Cited by 6
Related Papers
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
CD4+ T Cell Depletion during all Stages of HIV Disease Occurs Predominantly in the Gastrointestinal Tract
|The Journal of Experimental Medicine|2004|1.8k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Anthracycline Dose Intensification in Acute Myeloid Leukemia
|New England Journal of Medicine|2009|907